Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Gilson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|June 24, 2010
Autosomal dominant acute necrotising encephalopathy: a case report with possible disease-expression modification by coincidental homocysteinuriaClare Gilson, Robert McFarland, Rob Forsyth
The Practitioner|November 5, 2015
New developments in metastatic prostate cancer therapyThubeena Manickavasagar, Clare Gilson, Simon Chowdhury, et al.
European Urology|July 25, 2016
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial PlatformSilke Gillessen, Clare Gilson, Nick James, et al.
Intractable & Rare Diseases Research|December 19, 2018
Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasiaGavin Fatania, Clare Gilson, Alan Glover, et al.
The Laryngoscope|April 24, 2016
Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?Claire L Shovlin, Clare Gilson, Mark Busbridge, et al.
JCO Oncology Practice|May 23, 2025
Management of Testicular CancerDaniele Raggi, Deep Chakrabarti, Walter Cazzaniga, et al.
Trials|May 30, 2019
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocolsFrancesca Schiavone, Riya Bathia, Krishna Letchemanan, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|June 24, 2010
Autosomal dominant acute necrotising encephalopathy: a case report with possible disease-expression modification by coincidental homocysteinuriaClare Gilson, Robert McFarland, Rob Forsyth
The Practitioner|November 5, 2015
New developments in metastatic prostate cancer therapyThubeena Manickavasagar, Clare Gilson, Simon Chowdhury, et al.
European Urology|July 25, 2016
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial PlatformSilke Gillessen, Clare Gilson, Nick James, et al.
Intractable & Rare Diseases Research|December 19, 2018
Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasiaGavin Fatania, Clare Gilson, Alan Glover, et al.
The Laryngoscope|April 24, 2016
Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?Claire L Shovlin, Clare Gilson, Mark Busbridge, et al.
JCO Oncology Practice|May 23, 2025
Management of Testicular CancerDaniele Raggi, Deep Chakrabarti, Walter Cazzaniga, et al.
Trials|May 30, 2019
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocolsFrancesca Schiavone, Riya Bathia, Krishna Letchemanan, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Pageof 2